FIELD: medicine.
SUBSTANCE: invention is the use of 6-hydroxy-2,2,4-trimethyl-1,2,3,4-tetrahydroquinoline (hydroxy-THC) for the correction of oxidative status in modeling Parkinson's disease. The method includes intraperitoneal administration of hydroxy-THC for 10 days at a dose of 50 mg/kg of rat body weight in the form of an aqueous solution containing 0.9 wt. % of sodium chloryl and 5 vol. % of dimethyl sulfoxide, at the rate of 0.5 ml of solution per 0.2 kg of animal body weight.
EFFECT: invention provides improvement of motor-coordination parameters and reduction of parameters of free radical oxidation intensity in the brain and blood serum of animals.
1 cl, 1 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DRUG PREPARATION FOR PARKINSON DISEASE | 2014 |
|
RU2545734C1 |
| USE OF LACTOBACILLUS FERMENTUM U-21 STRAIN CELLS FOR PREVENTION OF PATHOLOGIC TISSUE CHANGE CAUSED BY OXIDATIVE STRESS | 2019 |
|
RU2757118C2 |
| PHARMACEUTICAL COMPOSITIONS FOR TREATING PARKINSON'S DISEASE | 2009 |
|
RU2540470C9 |
| METHOD FOR DIAGNOSING PARKINSON'S DISEASE ASSOCIATED WITH MUTATIONS IN GLUCOCEREBROSIDASE (GBA) GENE | 2020 |
|
RU2750357C1 |
| LACTOBACILLUS FERMENTUM U-21 STRAIN, WHICH PRODUCES COMPLEX OF BIOLOGICALLY ACTIVE SUBSTANCES WHICH NEUTRALIZE SUPEROXIDE ANION INDUCED BY CHEMICAL AGENTS | 2018 |
|
RU2705250C2 |
| USING THE ACETYLCHOLINESTERASE AND IDALOPIRDINE INHIBITOR TO REDUCE THE RISK OF FALLS IN THE PATIENTS WITH PARKINSON'S DISEASE | 2017 |
|
RU2742173C2 |
| COMPOSITION FOR TREATING PARKINSON'S DISEASE | 2017 |
|
RU2697411C2 |
| SET OF HOUSEKEEPING GENES FOR ANALYSIS OF GENE EXPRESSION IN PARKINSON'S DISEASE IN VARIOUS BRAIN AND PERIPHERAL BLOOD TISSUES OF MICE AND ITS APPLICATION | 2022 |
|
RU2798295C1 |
| METHOD OF EXPERIMENTAL MODEL OF PARKINSON'S DISEASE IN LABORATORY ANIMALS | 2022 |
|
RU2789823C1 |
| METHOD FOR EARLY DIAGNOSIS OF PARKINSON'S DISEASE | 2019 |
|
RU2722666C1 |
